Hertraz 440mg Injection contains Trastuzumab, a monoclonal antibody used primarily to treat HER2-positive cancers, such as breast and gastric cancers.

Brand Name: Hertraz

Composition: Trastuzumab

Mechanism of Action:

It emphasizes the HER2 receptor, a protein that some cancer cells' surfaces overexpress. Trastuzumab reduces tumor growth by binding to HER2 and blocking signaling pathways that promote cell growth and survival, designating the cells for immune destruction.

Uses:

• Gastric Cancer
• Breast Cancer

Dosage and Administration:

Depending on the protocol, usually 8 mg/kg, followed by a maintenance dose of 6 mg/kg every three weeks. Given as an intravenous infusion; in order to watch for any negative reactions, the first infusions are given gradually.

Side Effect:

• Nausea
• Vomiting
• Loss of appetite
• Diarrhea
• Fatigue
• Dizziness
• Sweating
• Stomatitis (mouth sores)
• Hand-foot syndrome
• Cardiotoxicity
• Liver enzyme elevation

Safety Advises:

Liver  

Periodic tests for liver function are recommended as the drug can cause toxicity, especially in patients with pre-existing conditions. Kindly speak with your healthcare provider.

Kidney  

Periodic tests for kidney function are recommended as the drug can cause toxicity, especially in patients with pre-existing conditions. Kindly speak with your healthcare provider.

Pregnancy  

Hertraz is contraindicated in pregnancy due to the risk of fetal harm. Kindly speak with your healthcare provider.

Breast Feeding  

Breastfeeding should be avoided, as the drug can be excreted in breast milk. Kindly speak with your healthcare provider.

Storage:

Store Hertraz Injection in the refrigerator at 2-8°C, protected from light, and avoid freezing.

How to use this Medication?

This medication is administered intravenously. A medical expert with specialized training administers it in a hospital or clinic.

Consult your pediatrician about this medication's use in kids. The use of this medication in minors is not authorized.

References:

1.      Boekhout AH, Beijnen JH, Schellens JH. Trastuzumab. The oncologist. 2011 Jun 1;16(6):800-10.

2.      Hudis CA. Trastuzumab—mechanism of action and use in clinical practice. New England journal of medicine. 2007 Jul 5;357(1):39-51.

3.      Hortobagyi GN. Trastuzumab in the treatment of breast cancer. New England Journal of Medicine. 2005 Oct 20;353(16):1734-6.

4.      Vu T, Claret FX. Trastuzumab: updated mechanisms of action and resistance in breast cancer. Frontiers in oncology. 2012 Jun 18;2:62.

Disclaimer:

The main goal of Apothecare Wellness is to make sure that the information it provides to customers is correct, reliable, and reviewed by specialists. This website's contents and information are strictly for informational purposes. They are not meant to be used in place of expert medical advice, diagnosis, or care. Please consult your physician for guidance and ask any questions you may have about any condition or medication. If you read anything on Apothecare Wellness, do not discount or delay obtaining competent medical advice. Our goal is to enhance the doctor-patient relationship, not to take its place.

Marketer details

Name: Mylan Pharmaceuticals Pvt Ltd - A Viatris Company

Address: Mylan Pharmaceuticals Private Limited , Commercial Operations , Prestige Tech Park,Platina-3, 7th to 12th floor, Prestige Tech Park, Kadubesanahalli, Bangalore -560103